AXL and neoplasm: In contrast to other mechanisms of resistance to EGFR TKi, in these tumor cells, AXL was neither mutated, amplified, nor its expression driven by EGFR TKi treatment as in the case of the persistent cells originally described by Sharma et al., 2010.